IDEXX

IDEXX Delivers Double-Digit Q4 Growth, Strong 2025 Performance; Issues Solid 2026 Outlook

IDEXX Laboratories reported strong fourth-quarter and full-year 2025 results driven by sustained growth in companion animal diagnostics, record instrument placements, and operating margin expansion, while providing a confident outlook for continued growth in 2026.

IDEXX Names Michael Erickson, PhD, as Next CEO; Jay Mazelsky to Become Executive Chair

Michael Erickson, PhD, will take over as President and CEO of IDEXX Laboratories in May 2026, succeeding Jay Mazelsky, who will transition to Executive Chair before retiring in 2027.

Topics

IDEXX Delivers Double-Digit Q4 Growth, Strong 2025 Performance; Issues Solid 2026 Outlook

IDEXX Names Michael Erickson, PhD, as Next CEO; Jay Mazelsky to Become Executive Chair

Zoetis to Acquire Neogen’s Animal Genomics Business for $160 Million, Expanding Precision Animal Health Portfolio

Zoetis to Participate in Bank of America 2026 Animal Health Summit

Tartar Shield Launches ‘Second Smile’ Initiative Integrating Preventive Dental Care Into Shelter Adoptions

Most U.S. Pet Owners Report High Satisfaction with Their Veterinary Practice, AVMA Data Show

FDA Grants Emergency Use Authorization for NexGard Products to Treat New World Screwworm in Dogs and Cats

FDA Approves NUMELVI™, First Second-Generation JAK Inhibitor for Canine Allergic Dermatitis